$Humacyte (HUMA.US)$In for 3000 shares as a gamble, if they keep their FDA approval and get some revenue from Symvess could be an easy 2x or 3x from here. Stock's pretty cheap rn too if FDA approval disappears then gg i guess
2
2
Report
72957079
:
What is that worth? Just ten thousand, not worth it! If you're going to do it, do it big, buy three hundred thousand shares!
$Humacyte (HUMA.US)$Humacyte CEO addresses concerns in NYT over FDA approval of Symvess Investing.com -- Dr. Laura Niklason, President and CEO of Humacyte, Inc. (NASDAQ:HUMA), responded to a New York Times (NYSE:NYT) article that questioned the FDA’s approval of Symvess for commercial sales earlier this week. Niklason had previously withheld comment due to the company b...
6
4
Report
topcing
:
yeah between lawyers eating every cent of profit. There is no reason to develope anything
Trytosaveabit
OPtopcing
:
Just saying! If it can be proven that he lied and was responsible for hurting the price? Well some repercussions for that would go a long way to discourage others from doing it!
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Humacyte Stock Discussion
seems to finds a stable supporrt level at 1.40
good for daytrade take profits
if FDA approval disappears then gg i guess
Humacyte Q4 Earnings: 34 Hospitals Eye New FDA-Approved Vascular Treatment
Investing.com -- Dr. Laura Niklason, President and CEO of Humacyte, Inc. (NASDAQ:HUMA), responded to a New York Times (NYSE:NYT) article that questioned the FDA’s approval of Symvess for commercial sales earlier this week. Niklason had previously withheld comment due to the company b...
No comment yet